Keratoacanthoma
☆ I le 2022 Stiftung Warentest i'uga mai Siamani, o le fa'amalieina o tagata fa'atau i ModelDerm sa na'o sina maualalo ifo nai lo fa'atalanoaga telemedicine totogi.
masani Keratoacanthoma
References
Keratoacanthoma (KA) ose tuma pa'u e masani ona iloa ona o lona tuputupu a'e vave ma e mafai ona toe solomuli na'o ia. E masani lava ona tupu i tama matutua, aulelei-pa'u ma se tala faasolopito o le la. E ui o le ta'otoga aveese e fa'aaoga ai le fa'aogaina po'o le Mohs micrographic taotoga o le togafitiga masani, e tele isi togafitiga e avanoa.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) ose tuma maualalo e amata i nisi ga'o i totonu o le pa'u ma foliga tutusa ma le squamous cell carcinoma (SCC) i lalo o le microscope. O loʻo faʻaauau pea felafolafoaiga pe tatau ona faʻavasega KA o se ituaiga o SCC osofaʻi.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) o le ituaiga lona lua e sili ona taatele o le kanesa i tagata, aemaise lava i tagata matutua. O le taotoga e masani ona faʻaaogaina e togafitia ai le cSCC, ae mo nisi o gasegase e le mafai ona faia se taotoga pe filifili e le faia, o isi filifiliga e pei o togafitiga faʻapitoa e mafai ona mafaufauina. Togafitiga fa'aleaganu'u (methotrexate or 5-fluorouracil) ua fa'aaogaina, ae o lo'o fa'aauau pea su'esu'ega i auala fou e pei ole tui ole tui ole tui ma le oncolytic virotherapy. O iinei, o le a tatou vaʻavaʻai ai i togafitiga faʻapitoa mo le cSCC, e amata mai i auala masani e oʻo atu i taʻiala sili.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
I lalo o le microscope, keratoacanthoma e matua latalata lava i le squamous cell carcinoma. A'o fa'avasega e nisi o foma'i fa'ama'i le keratoacanthoma ose vaega ma'oti ae le o se fa'ama'i, e tusa ma le 6% o fa'ama'i ma tala fa'asolopito keratoacanthoma o lo'o aga'iga'i i luma i le fa'aoso fa'ama'i ma le mata'utia o le kanesa squamous cell.
○ Suiga ma Togafiti
#Dermoscopy
#Skin biopsy